Houston, TX - (NewMediaWire) - November 21, 2022 - Sino Biological, Inc. (“Sino Biological” or the “Company”), a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical contract research services, is pleased to announce the formal signing of a lease with Hines and initiation of construction on its new Center for Bioprocessing (C4B) at its Levit Green facility in Houston, Texas USA.
Headquartered in Beijing, China with subsidiaries in Suzhou, China; Taizhou, China; Frankfurt, Germany; Kawasaki, Japan; and Wayne, Pennsylvania and listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), Sino Biological is the world’s leading provider of mammalian cell-based recombinant proteins, antibodies, and related contract research services. This new site serves as the company’s first US-based manufacturing facility. Referred to as the Center for Bioprocessing (C4B), the facility will focus on both product manufacture and the implementation of contract research services. Levit Green will further establish its presence in Houston, providing companies, academics, and medical researchers in the world-renowned Texas Medical Center and across the region invaluable access to Sino Biological’s comprehensive offering of bioreagents and CRO services.
Dr. Rob Burgess, Sino Biological’s Chief Business Officer, stated, “We are extremely excited about our new partnership with the Hines team and our forthcoming laboratories and production facilities at Levit Green. Hines is at the forefront of next-generation laboratory space design and development, and our new site at the Levit Green master-planned district in the heart of Houston’s Texas Medical Center will enable Sino Biological to considerably expand its research services and bioreagent manufacture capabilities into the United States.”
“I am delighted about the development of the Center for Bioprocessing in Houston. I believe strongly in excellent science and cutting-edge technologies, and that’s why I joined Sino Biological. I have assembled a world-class team which is currently establishing the C4B with the ultimate goal to promote the scientific development of next-gen precision medicine therapeutic antibodies and proteins,” stated Dr. Yingmin Zhu, the C4B’s Head.
“Levit Green was meticulously designed to provide best-in-class life science space that can accommodate a multitude of uses. Welcoming Sino Biological is a testament to the market need for sophisticated, flexible space that allows diversified firms to perform a variety of research,” said John Mooz, senior managing director of Hines. “Sino Biological is an excellent addition to the district’s growing life science ecosystem, and we look forward to supporting their continued growth and success.
About Sino Biological
Sino Biological is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies, and cDNA clones. Sino Biological is the researchers' one-stop technical services shop for the advanced technology platforms they need to make advancements. In addition, Sino Biological offers pharmaceutical companies and biotechnology firms pre-clinical production technology services for hundreds of monoclonal antibody drug candidates. To learn more about Sino Biological, visit www.sinobiological.com, follow us on LinkedIn or @SinoInc on Twitter.
Hines is a global real estate investment, development, and property manager. The firm was founded by Gerald D. Hines in 1957 and now operates in 28 countries. We manage a $92.3B¹ portfolio of high-performing assets across residential, logistics, retail, office, and mixed-use strategies. Our local teams serve 634 properties totaling over 225 million square feet globally. We are committed to a net zero carbon target by 2040 without buying offsets. To learn more about Hines, visit www.hines.com and follow @Hines on social media.
¹Includes both the global Hines organization as well as RIA AUM as of June 30, 2022.
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, over which Sino Biological and Hines have no control. Sino Biological and Hines assume no obligation to update these forward-looking statements and do not intend to do so.
View the original release on www.newmediawire.com